Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002115
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Phase III Study of the Safety Tolerance and Pharmacokinetics of 9-2-PhosphonylmethoxyethylAdenine PMEA Adefovir in Patients With Advanced HIV Disease
Sponsor:
Gilead Sciences
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase III Study of the Safety Tolerance and Pharmacokinetics of 9-2-PhosphonylmethoxyethylAdenine PMEA Adefovir in Patients With Advanced HIV Disease
Status:
COMPLETED
Status Verified Date:
1995-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To study the safety tolerance pharmacokinetics and anti-HIV effects of PMEA adefovir when administered daily by intravenous IV andor subcutaneous SC injection in patients with advanced HIV disease
Detailed Description:
Patients receive a single IV or SC dose of PMEA daily for 4 weeks A maximum tolerated dose will be defined for these regimens
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GS-92-202 | None | None | None |